Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of July 2022, with the report dated July 8, 2022. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) rather than a financial performance report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to specific share transactions:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Price: £17.8560 per share.
- Transaction Volume (CEO): 7,436.779 shares.
- Transaction Volume (CFO): 1,213.975 shares.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely discloses the acquisition of shares by executives following the re-investment of dividends paid on July 1, 2022.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory disclosure of share purchases made on the London Stock Exchange (XLON) on July 5, 2022, under the Company's Performance Share Plan, which includes a 2-year holding period.
Key Facts for Investor Verification
- CEO Emma Walmsley and CFO Ian Mackay acquired shares via dividend re-investment.
- The acquisition price was £17.8560 per share.
- The shares are subject to a 2-year holding period under the Performance Share Plan.
- This filing does not contain quarterly or annual financial results.